Skip to main content

Part of cannabis and investing

Canopy Growth Corp. has signed a deal that will see Martha Stewart join the company in an advisery role to help develop a new line of products.

Canopy Growth says it will use Stewart’s knowledge of consumer products while exploring the effectiveness of hemp-derived CBD and other cannabinoids as they relate to both humans and animals.

The U.S. recently signed the Farm Bill, which legalized the cultivation of hemp as a source of cannabidiol (CBD), one of the compounds also found in cannabis. Pot itself remains illegal under federal law south of the border. However, there are still grey areas, as the FDA also does not allow CBD-infused foods or beverages in interstate commerce and there are variations between states on how CBD-products can be distributed or what it can be added in to.

Story continues below advertisement

Ontario-based Canopy Growth – one of Canada’s largest producers of cannabis products for medical and recreational use – has developed diverse product offerings specific to hemp-derived CBD.

It has announced plans to invest between $100-million and $150-million in a hemp industrial park in New York State.

Canopy CEO Bruce Linton described Stewart’s fame as an expert in consumer products as a “one of a kind” collaborator.

“As soon as you hear the name Martha, you know exactly who we’re talking about,” Linton said in a statement.

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies